Conversation on Twitter :
@FierceBiotech: Special report: The Top Phase III Disasters of 2012. Report | Follow @FierceBiotech
@JohnCFierce: First "complete virtuous circle" for crowdfunding biotech model in France. Interesting idea. Hard to pull off. Release | Follow @JohnCFierce
@RyanMFierce: Nice to see VentiRx deal with Celgene, and a win for a biotech with small virtual staff and big potential. More | Follow @RyanMFierce
> Alimera Sciences has raised $40 million from the sale of its shares to institutional investors. Report
> Epizyme has earned a $4 million milestone from its partnership with GlaxoSmithKline ($GSK). Release
> The Leukemia and Lymphoma Society and Celgene have agreed to partner on research into new blood cancer treatments. Release
Pharma News
@FiercePharma: Novartis drops its legal case against U.K. doc group that nixed Lucentis. The group changed policy after Novartis cut price. More | Follow @FiercePharma
> Private equity's pharma hopes exemplified by Nycomed. More
> Celgene's Abraxane delivers in melanoma study. Article
> Sanofi, Bristol revamp Plavix partnership for post-patent world. Story
> Sanofi buying Genfar as it rolls across Latin America. News
@FierceMedDev: Paper Dx could become even cheaper if this new research finding catches on. More | Follow @FierceMedDev
@MarkHFierce: The U.S. breast implant market will grow modestly in the coming years, Millennium estimates, but Europe's won't. More | Follow @MarkHFierce
@DamianFierce: Fresh off its $100M IPO, Globus Medical got FDA approval for its spinal disc implant. More | Follow @DamianFierce
> Analysts: Device market growth will outpace pharma by 2018. News
> Allergan abandons pursuit of FDA clearance for teen use of Lap-Band obesity device. Article
Biomarkers News
> Singulex heads for $86.25M flotation. Item
> RNA profiles pinpoint the course of MS. Story
> Biomarkers boost success, cut costs in breast cancer clinical trials. Article
> Singulex heads for $86.25M flotation. More
Drug Delivery News
> Pfizer pays out on Antares drug delivery tech agreement. News
> Nanoparticles getting under your skin? Maybe not, actually. Story
> Noven ADHD patch heads into Phase II. Article
And Finally… Investigators at Texas A&M have been probing into the reason why phobias are so difficult to treat. Story